Combination | Company | Mechanism | phase | NCT number |
---|---|---|---|---|
Combination SRF617 with pembrolizumab gemcitabine albuminbound paclitaxel | Surface Oncology Merck Sharp & Dohme LLC | CD39 antagonist with chemotherapy | Phase I | NCT04336098 |
Combination TTX-030 with immunotherapy and/or chemotherapy | Trishula Therapeutics, Inc. AbbVie | Anti-CD39 antibody with immunotherapy | Phase I | NCT04306900 |
Combination SRF617 with AB928 (Etrumadenent) and AB122 (zimberelimab) | Surface Oncology Arcus Biosciences, Inc | Anti-CD39 antibody with A2AR and A2BR antagonist | Phase I | NCT05177770 |
Combination IPH5301 with chemotherapy and trastuzumab | Institut Paoli-Calmettes Innate Pharma | Anti-CD73 antibody with chemotherapy | Phase I | NCT05143970 |
Combination AK119 with AK104 | Akeso | Anti-CD73 antibody with chemotherapy | Phase I | NCT04572152 |
Combination IBI325 with sintilimab | Innovent Biologics (Suzhou) Co. Ltd. | Anti-CD73 antibody with chemotherapy | Phase I | NCT05119998 |
Combination oleclumab with gemcitabine, nab-paclitaxel, durvalumab | M.D. Anderson Cancer Center | Anti-CD73 antibody with chemotherapy | PhaseII | NCT04940286 |
Combination dalutrafusp (GS-1423) with mFOLFOX6 regimen | Gilead Sciences | Anti-CD73-TGFβ-Trap antibody with chemotherapy | Phase I | NCT03954704 |
Combination LY3475070 with pembrolizumab | Eli Lilly and Company Merck Sharp & Dohme LLC | CD73 antagonist with immunotherapy | Phase I | NCT04148937 |
Combination BMS-986179 with nivolumab (BMS-936558) | Bristol-Myers Squibb | CD73 antagonist with immunotherapy | Phase II | NCT02754141 |
Combination INCA00186 with INCB106385 and/or retifanlimab | Incyte Corporation | CD73 antagonist with immunotherapy | Phase I | NCT04989387 |
Combination TJ004309 with atezolizumab | I-Mab Biopharma US Limited I-Mab Biopharma Co. Ltd. | Anti-CD73 antibody with immunotherapy | Phase II | NCT05001347 |
Combination JAB-BX102 with pembrolizumab | Jacobio Pharmaceuticals Co., Ltd. | Anti-CD73 antibody with immunotherapy | Phase II | NCT05174585 |
Combination PT199 with an anti-PD-1 monoclonal antibody | Phanes Therapeutics | Anti-CD73 antibody with immunotherapy | Phase I | NCT05431270 |
Combination NZV930 with PDR001 | Novartis Pharmaceuticals Novartis | Anti-CD73 antibody with immunotherapy | Phase I | NCT03549000 |
Combination Sym024 with Sym021 | Symphogen A/S | Anti-CD73 antibody with immunotherapy | Phase I | NCT04672434 |
Combination oleclumab (MEDI9447) with AZD4635 | MedImmune LLC | Anti-CD73 antibody with A2AR antagonist | Phase Ib/II | NCT03381274 |
Combination CPI-006 with ciforadenant or pembrolizumab | Corvus Pharmaceuticals, Inc | Anti-CD73 antibody with A2AR antagonist | Phase I | NCT03454451 |
Combination inupadenant (EOS100850) with Chemotherapy | iTeos Belgium SA iTeos Therapeutics | A2AR antagonist with chemotherapy | Phase II | NCT05403385 |
Combination INCB106385 with immunotherapy | Incyte Corporation | A2AR antagonist with immunotherapy | Phase I | NCT04580485 |
Combination NZV930 with PDR001 and /or NIR178 | Novartis Pharmaceuticals Novartis | A2AR antagonist with immunotherapy | Phase I | NCT03549000 |
Combination lpilimumab, nivolumab with ciforadenant (CPI-444) | M.D. Anderson Cancer Center | A2AR antagonist with immunotherapy | phase I/II | NCT05501054 |
Combination NIR178 with PDR001 | Novartis Pharmaceuticals Novartis | A2AR antagonist with immunotherapy | Phase II | NCT03207867 |
Combination taminadenant with PDR001 | Palobiofarma SL Novartis H. Lee Moffitt Cancer Center and Research Institute | A2AR antagonist with immunotherapy | Phase I | NCT02403193 |
Combination DFF332, spartalizumab with taminadenant | Novartis Pharmaceuticals Novartis | A2AR antagonist with immunotherapy | Phase I | NCT04895748 |
Combination AZD4635 with durvalumab or oleclumab (MEDI9447) | AstraZeneca | A2AR antagonist with anti-CD73 antibody | Phase II | NCT04089553 |